Safety of biologic therapy

Inflammatory Bowel Diseases

Volumn 13, Issue 6, 2007, Pages 769-796

  Blonski, Wojciech ^a   Lichtenstein, Gary R ^b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse events; Biologic agents; Crohn's disease; Ulcerative colitis

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; ALPHA INTERFERON; BETA INTERFERON; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; EPIDERMAL GROWTH FACTOR; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MLN 02; ONERCEPT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; REPIFERMIN; SEMAPIMOD; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG USE; EDEMA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INTESTINE MUCOSA; MOTOR NEUROPATHY; MYALGIA; NAUSEA; OPTIC NEURITIS; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; BIOLOGICAL THERAPY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; REMISSION INDUCTION; T-LYMPHOCYTES; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250310755     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20027     Document Type: Review

References (105)

1. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004;53:1366-1373.
2. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-608.
3. Brown S, Abreu M. Biologic therapies in inflammatory bowel disease. Practical Gastroenterology. 2005;XXIX:38-63.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476.
5. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157.
6. Remicade (Infliximab). Prescribing information. 2005.
7. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
8. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
10. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
11. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97: 2962-2972.
12. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003;52:1728-1733.
13. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
14. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
15. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
16. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1-51.
17. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-1087.
18. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015-2019.
19. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047-1052.
20. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994;107: 1675-1679.
21. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308-2312.
22. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
23. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647-653.
24. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
25. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117: 761-769.
26. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
27. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317(7152):180-181.
28. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.
29. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738.
30. Lichtenstein GR, Cohen R, Feagan B, et al. Safety of infliximab and other Crohn's disease therapies-updated TREAT registry data with over 10,000 patients-years of follow-up. Gastroenterology. 2O05;128:W 1034.
31. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-524.
32. Feagan B, Sandborn W, Baker J, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology. 2000;118:A655.
33. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338.
34. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493.
35. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997;11:1031-1035.
36. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17(2):185-192.
37. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:888-893.
38. Enbrel. Prescribing information. 2005.
39. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol. 2001;96:2564-2568.
40. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
41. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002;122(1):7-14.
42. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther. 2004;20(11-12):1337-1346.
43. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
44. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
45. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1989.
46. Sandborn W, Hanauer S, Lucas M, et al. Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-alpha monoclonal antibody adalimumab (Humira). Gastroenterology. 2005; 128:A-112-A-.
47. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004; 10:333-338.
48. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100(1):75-79.
49. Hinojosa J, Garcia S, Bastida G, et al. Efficacy and safety of 4 weeks of adalimumab treatment in subjects with active luminal Crohn's disease who lost response or showed intolerance to infliximab. Gastroenterology. 2006;130:A-656.
50. Hinojosa J, Gomollon F, Nos P, et al. Four weeks results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab. Gastroenterology. 2006;130:A-120.
51. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114:1133-1142.
52. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology. 2001;120:1339-1346.
53. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51(1):30-36.
54. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther. 2002;16:1761-1770.
55. Chey WY VM, Konecny M, Rydzewska G, Fogel R, Pare P. Two phase 3 studies of alicaforsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease. Gastroenterology. 2005;128:A-112.
56. Van Deventer S, Volfova M, Flisiak R, et al. A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left sided ulcerative colitis. Gastroenterology. 2005;128:A-74.
57. Miner P, Nichols T, Schwartz H, et al. A phase 2 trial to assess the safety and efficacy of two dose formulations of Alicaforsen enema compared with 4g mesalamine enema for acute ulcerative colitis. Gastroenterology. 2005;2005:A-74.
58. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D. 2004;5(2):102-107.
59. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
60. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
61. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925.
62. Sands B, Kozarek R, Spainhour J, et al. Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease. Gastroenterology. 2004;126:A-463.
63. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16:699-705.
64. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368.
65. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-381.
66. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-374.
67. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med. 2005;353:432-433.
68. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507.
69. Inc. MP. Available at: http://www.mlnm.com/media/news/2002/ 2002%2D09%2D16%2D0.asp. Accessed May 8, 2005.
70. Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther. 2005;22(2):111-122.
71. Plevy S, Salzberg B, Van Assche G, et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology. 2004;126:A-75.
72. Targan S, Salzberg B, Mayer L, et al. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids. Gastroenterology. 2005;128:A-75.
73. Hommes D, Targan S, Baumgart D, et al. A phase I study: visilizumab therapy in Crohn's Disease (CD) patients refractory to infliximab therapy. Gastroenterology. 2006;130:A-111.
74. Rutgeerts P, Van Deventer S, Schreiber S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther. 2003;17:1435-1450.
75. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383-389.
76. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472.
77. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
78. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. 2001;49(1):42-46.
79. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999;117(1):58-64.
80. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther. 2002;16:399-406.
81. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002;8:567-573.
82. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
83. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665-674.
84. Walker KB, Potter JM, House AK. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol. 1987;68(1):162-167.
85. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18(1):65-75.
86. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003;98:369-376.
87. Rutgeerts P, Reinisch W, Colombel JF, et al. Preliminary results of a phase I/II study of Huzaf, an anti-INFγ monoclonal antibody, in patients with moderate to severe active Crohn's disease. Gastroenterology. 2002;122:A-61.
88. Hommes D, Mikhajlova T, Stoinov S, et al. Fontolizumab (Huzaf), a humanized anti-INF-γ antibody, has a clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology. 2004;127:332.
89. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med. 2000;342: 1633-1637.
90. Sung C, Parry TJ, Riccobene TA, et al. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. AAPS PharmSci. 2002;4(2):E8.
91. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003;17:1355-1364.
92. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349:350-357.
93. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol. 1995;7:597-602.
94. Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol. 2001;96:1807-1815.
95. Nikolaus S, Rutgeerts P, Fedorak RN, et al. Recombinant human interferon-beta (IFN-β-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology. 2001;120: A-454.
96. Davidsen B, Munkholm P, Schlichting P, et al. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther. 1995;9(1):75-79.
97. Gasche C, Reinisch W, Vogelsang H, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci. 1995;40:800-804.
98. Hommes DW, Meenan J, Dijkhuizen S, et al. Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis. Clin Exp Immunol. 1996;106:529-533.
99. Melis D, Parenti G, Delia Casa R, et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs. Acta Paediatr. 2003;92:1415-1421.
100. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med. 1999;340:239-240.
101. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478-1480.
102. Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion. 2003;68(2-3):63-70.
103. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992;102:514-519.
104. Ito H, Takazoe M, Fukuda Y, et al. Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial. Gastroenterology. 2003;124:A-25.
105. Travis S, Yap LM, Hawkey C, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005; 11:713-719.